Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) is relocating its global headquarters to New York City, centralizing corporate leadership in the U.S. as part of its global growth strategy in minimally invasive microwave ablation technology.

The move follows the December 2025 appointment of Mark Saxton as CEO of the U.S. subsidiary to lead domestic operations and commercial expansion. The New York headquarters is intended to improve access to U.S. healthcare investors and support a growing national sales force and physician/KOL network, while global operations continue across key healthcare markets.

Positive

• Global headquarters relocated to New York City, centralizing corporate leadership in the U.S.
• U.S. operational buildout described as progressing on schedule
• Strategic investments in commercial and clinical initiatives to support microwave ablation treatments

Negative

• None.

Market Context

This announcement centers on relocating global headquarters to New York to reinforce U.S. commercial...

Analysis

This announcement centers on relocating global headquarters to New York to reinforce U.S. commercial expansion and centralize leadership. It follows prior steps such as appointing a U.S. CEO and building production and educational infrastructure. Historically, BDMD’s stock reaction to growth and regulatory news has been inconsistent, ranging from a -14.34% move on Argentina clearance to +38.15% on its AI software filing. Investors may track execution on U.S. sales growth, global registrations, and use of the US$50,000,000 shelf capacity.

Historical Context

5 past events · Latest: Apr 29 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Full-year earnings	Negative	+1.8%	Reported 2025 revenue decline and operating loss alongside U.S. expansion plans.
Mar 16	Clinical workshops	Positive	+0.8%	Conducted expert-led MWA training workshops to support Southeast Asia adoption.
Mar 12	Regulatory clearance	Positive	-14.3%	Gained MWA regulatory clearance in Argentina, expanding international certifications.
Mar 09	Conference showcase	Positive	-7.4%	Showcased MWA at NASIT 2026 to advance U.S. interventional thyroidology presence.
Mar 04	AI software filing	Positive	+38.1%	Announced AI-driven surgical software development and multi-region registrations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News flow has been largely expansion-focused, but price reactions have been mixed, with several positive operational updates met by negative moves and the major AI software milestone drawing the strongest positive response.

Recent Company History

Over the last six months, BDMD has reported shrinking 2025 revenue of $22.5M versus $37.0M in 2024 and a larger loss, while simultaneously pushing global and U.S. expansion. It secured regulatory clearance in Argentina, ran clinical workshops in Indonesia, and advanced U.S. presence at NASIT 2026. An AI-driven surgical software registration update on Mar 4, 2026 produced the strongest move, highlighting investor focus on technology leverage and commercialization progress linked to these initiatives.

Key Terms

microwave ablation

1 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enhanced U.S. Presence Centralizes Operations as Company Executes Global Growth Strategy

NEW YORK, June 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the relocation of its global headquarters to the U.S., with the establishment of a new corporate office in New York, NY.

The relocation follows the December 2025 appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary to lead domestic operations, commercial expansion, and market development, establishing a Company beachhead in a premier global healthcare and financial hub.

"Relocating our global headquarters to New York marks the next step in Baird Medical's evolution as we continue to expand our commercial footprint and execute on our growth strategy as a leading global medtech company for innovative, minimally invasive ablation technologies and beyond," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "This move provides more efficient access to the world's most sophisticated healthcare investors and better positions us to support our growing sales force and physician and KOL network across the country."

While Baird Medical's physical presence will continue to span key healthcare markets globally, the new global headquarters will serve as a central hub for corporate leadership and strategic initiatives.

"Our U.S. operational buildout is progressing on schedule," added Haimei Wu, Chairwoman & CEO of Baird Medical. "We are building the infrastructure necessary to scale the business, making strategic investments in commercial and clinical initiatives to deliver safe, effective, and minimally invasive treatment solutions to patients worldwide."

About Baird Medical

Baird Medical is a pioneering medical device company specializing in minimally invasive diagnostics, treatment, and surgical robotic systems. Driven by a mission to enhance patient outcomes through precision technology, the Company extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies.

As an FDA 510(k)-certified medical device company, Baird Medical's solutions are utilized by over 30 prestigious U.S. institutions, including the Mayo Clinic, Columbia University Medical Center, UCSF Medical Center, and Weill Cornell Medical Center. Baird Medical is the market leader for thyroid microwave ablation devices in China and is rapidly expanding its commercial footprint across more than 20 countries. To fuel future innovation, the company actively fosters strategic collaborations with leading academic institutions worldwide.

Contact:
Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-establishes-global-headquarters-in-new-york-city-reinforcing-commitment-to-us-commercial-expansion-302794623.html

SOURCE BDMD

FAQ

What did Baird Medical (NASDAQ: BDMD) announce on June 9, 2026 about its headquarters?

Baird Medical announced the relocation of its global headquarters to New York City. According to Baird Medical, the new office will serve as the central hub for corporate leadership and strategic initiatives while maintaining a global presence in key healthcare markets.

Why is Baird Medical (BDMD) moving its global headquarters to New York?

Baird Medical is moving its headquarters to New York to support U.S. commercial expansion. According to Baird Medical, the location improves access to sophisticated healthcare investors and better supports its growing sales force, physicians, and key opinion leader network across the United States.

How does the new Baird Medical (BDMD) headquarters impact its U.S. growth strategy?

The new New York headquarters is positioned as a core part of Baird Medical’s U.S. growth strategy. According to Baird Medical, it centralizes leadership, aligns with ongoing U.S. operational buildout, and supports strategic investments in commercial and clinical initiatives for minimally invasive ablation technologies.

What role does CEO Mark Saxton play in Baird Medical’s U.S. expansion (BDMD)?

Mark Saxton was appointed CEO of Baird Medical’s U.S. subsidiary in December 2025 to lead domestic operations. According to Baird Medical, he oversees U.S. commercial expansion and market development, with the New York headquarters reinforcing this leadership role and local presence.

Will Baird Medical (BDMD) maintain its global operations after moving headquarters to New York?

Yes, Baird Medical plans to maintain its physical presence in key healthcare markets worldwide. According to Baird Medical, the New York global headquarters will coordinate corporate leadership while international operations continue to support minimally invasive microwave ablation treatments for patients globally.

What clinical focus does Baird Medical (BDMD) highlight with its New York headquarters move?

Baird Medical emphasizes its focus on minimally invasive microwave ablation treatment solutions. According to Baird Medical, it is making strategic investments in commercial and clinical initiatives aimed at delivering safe, effective, minimally invasive therapies to patients worldwide from its new New York–based global hub.